Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Evotec AG ( (EVO) ).
Evotec SE, a Germany-based life science and drug discovery specialist, has built proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modelling, alongside its Just – Evotec Biologics unit for biologics development and manufacturing. The company maintains a portfolio of more than 100 largely co-owned R&D assets with a focus on oncology, cardiovascular and metabolic diseases, neurology and immunology.
On April 29, 2026, Evotec announced the nomination of Dr. Wolfgang Hofmann as an independent member of its Supervisory Board, to be voted on at the Annual General Meeting scheduled for June 11, 2026. The AGM will also consider the previously announced nomination of Dieter Weinand as Supervisory Board Chairman and a proposal to expand the Supervisory Board from six to seven members, moves aimed at strengthening governance and supporting the company’s ongoing transformation.
The company simultaneously disclosed a cooperation agreement with major shareholder MAK Capital Fund LP, following what both sides described as constructive discussions. The pact, under which MAK Capital has agreed to customary voting and cooperation commitments, underscores Evotec’s emphasis on active shareholder engagement and is intended to bolster long-term value creation and governance stability for investors.
The most recent analyst rating on (EVO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
The score is held down primarily by weak financial performance (persistent losses and negative free cash flow) and bearish longer-term technicals (below key moving averages, negative MACD). The earnings call adds partial support via cost-savings progress, strong biologics performance, and liquidity, but 2026 transition-year guidance and D&PD weakness temper the outlook; valuation is also constrained by negative earnings and no dividend yield.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a global life science company focused on drug discovery and development, integrating AI-driven innovation and advanced technologies to accelerate the path from concept to cure. The company offers services across small molecules, biologics, cell therapies and related modalities, working with all Top 20 pharma companies, more than 800 biotechs and academic partners, and operates over 4,500 staff across Europe and the U.S.
Average Trading Volume: 157,835
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.04B
For an in-depth examination of EVO stock, go to TipRanks’ Overview page.